# Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis

> **NCT07503587** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 378 (estimated)

## Conditions studied

- Progressive Pulmonary Fibrosis

## Interventions

- **DRUG:** HSK44459
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07503587
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-05
- **Primary completion:** 2028-12-30
- **Final completion:** 2029-03-01
- **Target enrollment:** 378 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07503587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07503587, "Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07503587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*